Phase I/II trial of DEBIO 0932 + everolimus in patients wit6h renal cell carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2013
Price : $35 *
At a glance
- Drugs CUDC 305 (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Curis; Debiopharm
- 22 Oct 2013 Status changed from planning to recruiting, as reported by a media release from Debiopharm and Curis Inc.
- 10 Dec 2012 New trial record